Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine

Abstract

All these perspectives encourage further studies focused on anti-MET agents in different contexts of lung cancer. Probably, in the forthcoming future, considering the potential role of molecular MET testing as a predictor of efficacy of anti-MET therapy, it would be included in the routine panel of targetable molecular alteration of NSCLC. Before to move to such important step, the standardization of MET evaluation assays with the crucial definition of reliable (and reproducible) cut-offs is absolutely required to clearly identify those MET dysregulated NSCLC patients who would best benefit from MET-targeted therapy